查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
肌肉减少症市场－全球及区域分析：按治疗层级、给药途径、通路和地区分類的分析和预测（2025-2035 年）
市场调查报告书
商品编码
1856055

肌肉减少症市场－全球及区域分析：按治疗层级、给药途径、通路和地区分類的分析和预测（2025-2035 年）

Sarcopenia Market - A Global and Regional Analysis: Focus on Treatment Class, Route of Administration, Distribution Channel, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

老年人口的快速成长显着提高了全球肌肉萎缩性疾病的盛行率，从而推动了全球肌肉减少症市场的发展。随着60岁及以上人口数量的持续增长，尤其是在已开发国家和新兴国家，对肌肉减少症诊断和治疗的需求正在迅速扩大。此外，握力评估、步速测试和双能量X光检测法（DXA）等诊断工具的进步，提高了早期发现肌肉减少症的能力。

临床意识的提高使得肌肉减少症的检出率更高，有助于及时介入。此外，我们见证了治疗药物创新的显着进展，尤其是在荷尔蒙治疗（如睪固酮替代疗法）和靶向合成代谢肌肉通路生物製药（如肌肉生长抑制素抑制剂和选择性雄激素受体调变器(SARMs)）的研发方面。这些进展为更有效、更有针对性地管理老年族群的肌肉减少症提供了充满希望的途径。

阻碍市场成长的主要挑战之一是缺乏国际统一的诊断标准。诊断标准的差异，例如欧洲老年医学会（EWGSOP）、亚洲老年医学会（AWGS）和其他区域组织提出的标准，导致肌肉减少症的识别和分类不一致，阻碍了大规模临床研究、监管核准和治疗标准化。此外，肌肉减少症相关疗法（尤其是营养补充剂和非药物疗法）的保险覆盖范围和报销有限，限制了患者的就医途径，也降低了医疗机构采用这些疗法的动机。

全球肌肉减少症市场在新兴医疗保健趋势和技术进步的推动下，蕴藏着巨大的发展机会。快速的都市化进程、不断完善的医疗基础设施以及新兴国家（尤其是亚太和拉丁美洲地区）日益增长的老龄人口，正为市场扩张开闢新的途径。这些地区正越来越多地采用各种解决方案来预防和治疗与老龄化相关的疾病，从而为肌肉减少症干预创造了巨大的潜力。在技​​术创新的前沿，一些公司正在探索再生医学和干细胞治疗方法，例如MyoPax GmbH和远端医疗 Biotechnologies等公司开发的疗法，旨在从细胞层面恢復肌肉功能并逆转肌肉退化。此外，穿戴式装置、远距医疗平台和人工智慧肌肉监测应用程式等数位健康工具的整合，正在提升早期诊断、患者参与度和长期疾病管理水平。这些进步正在共同再形成肌肉减少症的格局，为全球老龄人口提供个人化、便利且技术驱动的医疗服务。

市场分类

细分 1：依治疗层级

  • 营养补充品
    • 蛋白质补充品（乳清蛋白、酪蛋白、胶原蛋白）
    • 胺基酸补充剂（亮氨酸、HMB、肌酸）
    • 维生素D和钙补充剂
    • 维生素B12和叶酸补充剂
    • Omega-3脂肪酸补充剂
  • 製药
    • 荷尔蒙补充疗法（睪酮及类似物质）
    • 血管紧张素转换酶抑制剂/血管收缩素II受体阻断剂
    • 其他（生长激素促分泌剂）
  • 联合治疗

细分 2：依给药途径

  • 口服
  • 肠外
  • 经皮/局部

细分3：按分销管道

  • 医院药房
  • 零售药房
  • 网路药房
  • 其他的

细分 4：按地区

  • 北美洲
  • 欧洲
  • 亚太地区

肌肉减少症市场正经历着变革性的趋势，这些趋势正在重塑研究、开发和交付格局。其中一个显着的趋势是人工智慧在药物研发中的应用日益广泛，企业利用先进的演算法来识别新的治疗靶点，并加速开发针对肌肉萎缩的精准疗法。这种技术整合缩短了药物上市时间，并实现了更具针对性和成本效益的药物研发。同时，联合治疗也越来越受欢迎，它将药物与营养补充剂和物理疗法相结合，以期在改善肌肉质量和功能方面产生协同效应。这种多模态策略正在获得临床支持，并改善患者的治疗效果。

本报告检视了全球肌少症市场，并总结了关键趋势、市场影响因素分析、法律规范、市场规模趋势和预测、按各个细分市场和主要国家/地区进行的详细分析、竞争格局以及主要企业的概况。

目录

执行摘要

第一章 全球肌肉减少症市场：产业分析

  • 市场概览与生态系统
  • 价值链分析
  • 主要市场趋势
    • 影响分析
  • 监管状态
  • 市场动态
    • 概述
    • 市场驱动因素
    • 市场限制
    • 市场机会

2. 全球肌肉减少症市场依治疗层级

  • 营养补充品
    • 蛋白质补充品（乳清蛋白、酪蛋白、胶原蛋白）
    • 胺基酸补充剂（亮氨酸、HMB、肌酸）
    • 维生素D和钙补充剂
    • 维生素B12和叶酸补充剂
    • Omega-3脂肪酸补充剂
  • 製药
    • 荷尔蒙补充疗法（睪酮及类似物质）
    • 血管紧张素转换酶抑制剂/血管收缩素II受体阻断剂
    • 其他（生长激素促分泌剂）
  • 联合治疗

3. 全球肌肉减少症市场（依给药途径划分）

  • 口服
  • 肠外
  • 经皮/局部

4. 全球肌肉减少症市场按分销管道划分

  • 医院药房
  • 零售药房
  • 网路药房
  • 其他的

5. 全球肌少症市场（按地区划分）

  • 北美洲
  • 欧洲
  • 亚太地区
  • 其他地区
    • 市场动态
    • 市场规模及预测
    • 市场规模及预测：依国家划分

6. 全球肌肉减少症市场的竞争格局与公司概况

  • 竞争格局
  • 公司简介
    • Nestle Health Science
    • Abbott Laboratories
    • Bayer AG
    • Sanofi SA
    • Novartis AG
    • Eli Lilly and Company
    • MyoPax GmbH
    • Amgen Inc.
    • Pfizer Inc
    • GlaxoSmithKline plc
    • 其他的

第七章调查方法

Product Code: BHL3353SA

Global Sarcopenia Market, Analysis and Forecast: 2025-2035

Sarcopenia is a progressive musculoskeletal disorder characterized by the loss of skeletal muscle mass, strength, and function, predominantly affecting older adults. It is clinically diagnosed based on the presence of three primary indicators: reduced muscle strength, diminished muscle quantity or quality, and impaired physical performance. This condition not only limits an individual's ability to perform daily tasks but also serves as a strong predictor of adverse postoperative outcomes, including higher rates of complications, morbidity, and mortality. Moreover, sarcopenia significantly increases the risk of falls and fractures, particularly in aging populations, and contributes to loss of independence in individuals over 90 years old. Due to its rising clinical significance, sarcopenia has been officially classified with a unique ICD-10 code to aid in diagnosis and differentiation from other muscle-wasting conditions.

The etiology of sarcopenia is multifactorial, with aging being the most prominent contributing factor. Globally, the prevalence is estimated at approximately 10% in individuals aged 60 and older and can reach up to 50% or higher in those aged 80 and above. These estimates vary widely due to differing diagnostic methods and heterogeneous populations across studies. While sarcopenia affects both men and women, its progression is closely tied to age-related biological changes, sedentary lifestyles, poor nutrition, and comorbidities. As the global population ages, sarcopenia is emerging as a critical public health concern, underscoring the urgent need for standardized diagnostic criteria and effective therapeutic strategies. The global Sarcopenia market faces several restraints and challenges that can hinder its growth. One significant barrier is the high cost of branded medications, such as Soolantra and Oracea, which limits affordability and access for many patients, particularly in low-income or uninsured populations.

The global sarcopenia market is primarily driven by the accelerating growth of the aging population, which significantly increases the prevalence of muscle-wasting conditions worldwide. As the number of individuals aged 60 and above continues to rise, particularly in developed and emerging economies, the demand for sarcopenia diagnosis and treatment is expanding rapidly. Additionally, advancements in diagnostic tools-such as handgrip strength assessments, gait speed testing, and imaging techniques like DXA (dual-energy X-ray absorptiometry)-have improved the ability to detect sarcopenia at earlier stages. This heightened clinical awareness has led to more frequent identification of the condition, promoting timely interventions. Furthermore, the market is witnessing robust progress in therapeutic innovation, especially in the development of hormonal treatments like testosterone replacement and biologics targeting muscle anabolic pathways, such as myostatin inhibitors and selective androgen receptor modulators (SARMs). These advancements offer promising avenues for more effective and targeted management of sarcopenia in aging populations.

The growth of the global sarcopenia market is constrained by several critical challenges, foremost among them being the lack of a universally accepted diagnostic standard. Variations in diagnostic criteria-such as those proposed by EWGSOP, AWGS, and other regional bodies-lead to inconsistencies in identifying and classifying sarcopenia, hindering large-scale clinical research, regulatory approval, and treatment standardization. Additionally, limited insurance coverage and reimbursement for sarcopenia-related therapies, particularly nutritional supplements and non-pharmaceutical interventions, restrict patient access and discourage provider adoption.

The competitive landscape of the global sarcopenia market is evolving swiftly, fueled by advancements in therapeutic innovation, strategic partnerships, and an expanding focus on aging-related healthcare. Leading players such as Nestle Health Science, Abbott Laboratories, Biophytis, MyoPax GmbH, and Lipocine Inc. are actively investing in research and development to address the multifactorial nature of sarcopenia. These efforts include the development of targeted therapies such as selective androgen receptor modulators (SARMs), myostatin inhibitors, regenerative stem cell treatments, and advanced nutritional formulations enriched with protein, creatine, and omega-3 fatty acids. Companies are also leveraging digital health tools-including remote monitoring apps, telehealth platforms, and AI-driven diagnostic aids-to enhance patient engagement and adherence. Concurrently, there is a growing emphasis on formulating personalized and combination therapies that integrate pharmaceutical, nutritional, and physical interventions. This innovation-centric, multidisciplinary approach is reshaping the sarcopenia market landscape with a focus on efficacy, long-term functionality, and improved quality of life for the aging global population.

The global sarcopenia market presents significant opportunities driven by emerging healthcare trends and technological advancements. Rapid urbanization, improving healthcare infrastructure, and growing geriatric populations in emerging economies-particularly across Asia-Pacific and Latin America-are opening new avenues for market expansion. These regions are increasingly adopting preventive and therapeutic solutions for age-related conditions, creating untapped potential for sarcopenia interventions. At the forefront of innovation, companies are exploring regenerative medicine and stem cell-based therapies, such as those developed by MyoPax GmbH and Turn Biotechnologies, which aim to restore muscle function and reverse muscle degeneration at the cellular level. Additionally, the integration of digital health tools-including wearable devices, telemedicine platforms, and AI-enabled muscle monitoring apps-is enhancing early diagnosis, patient engagement, and long-term disease management. Together, these advancements are reshaping the sarcopenia landscape by promoting personalized, accessible, and tech-enabled care for aging populations worldwide.

Market Segmentation:

Segmentation 1: by Treatment Class

  • Nutritional Supplements
    • Protein Supplements (Whey, Casein, Collagen)
    • Amino-Acid Supplements (Leucine, HMB, Creatine)
    • Vitamin D and Calcium Supplements
    • Vitamin B12 and Folate Supplements
    • Omega-3 Fatty-Acid Supplements
  • Pharmaceuticals
    • Hormone-Replacement Therapy (Testosterone & Analogues)
    • ACE Inhibitors and Angiotensin II Receptor Blockers
    • Others (Growth-Hormone Secretagogues)
  • Combination Therapies

Segmentation 2: by Route of Administration

  • Oral
  • Parenteral
  • Transdermal / Topical

Segmentation 3: by Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Segmentation 4: by the Region

  • North America
  • Europe
  • Asia-Pacific

The sarcopenia market is witnessing transformative trends that are reshaping its research, development, and delivery landscape. One notable trend is the increasing adoption of artificial intelligence (AI) in drug discovery where companies are using advanced algorithms to identify novel therapeutic targets and accelerate the development of precision treatments for muscle wasting. This technological integration is reducing time-to-market and enabling more targeted, cost-effective drug development. Simultaneously, there is a growing preference for combination therapy approaches that integrate pharmaceutical agents with nutritional supplements and physical therapy to achieve synergistic effects in improving muscle mass and function. These multi-modal strategies are gaining clinical support and improving patient outcomes.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Sarcopenia Market: Industry Analysis

  • 1.1 Market Overview and Ecosystem
  • 1.2 Value chain Analysis
  • 1.3 Key Market Trends
    • 1.3.1 Impact Analysis
  • 1.4 Regulatory Landscape
  • 1.5 Market Dynamics
    • 1.5.1 Overview
    • 1.5.2 Market Drivers
    • 1.5.3 Market Restraints
    • 1.5.4 Market Opportunities

2. Global Sarcopenia Market (by Treatment Class), Value ($million), 2023-2035

  • 2.1 Nutritional Supplements
    • 2.1.1 Protein Supplements (Whey, Casein, Collagen)
    • 2.1.2 Amino-Acid Supplements (Leucine, HMB, Creatine)
    • 2.1.3 Vitamin D and Calcium Supplements
    • 2.1.4 Vitamin B12 and Folate Supplements
    • 2.1.5 Omega-3 Fatty-Acid Supplements
  • 2.2 Pharmaceuticals
    • 2.2.1 Hormone-Replacement Therapy (Testosterone & Analogues)
    • 2.2.2 ACE Inhibitors and Angiotensin II Receptor Blockers
    • 2.2.3 Others (Growth-Hormone Secretagogues)
  • 2.3 Combination Therapies

3. Global Sarcopenia Market (by Route of Administration), Value ($million), 2023-2035

  • 3.1 Oral
  • 3.2 Parenteral
  • 3.3 Transdermal / Topical

4. Global Sarcopenia Market (by Distribution Channel, Value ($million), 2023-2035

  • 4.1 Hospitals Pharmacies
  • 4.2 Retail Pharmacies
  • 4.3 Online Pharmacies
  • 4.4 Others

5. Global Sarcopenia Market (by Region), Value ($Million), 2023-2035

  • 5.1 North America
    • 5.1.1 Market Dynamics
    • 5.1.2 Market Sizing and Forecast
    • 5.1.3 North America Sarcopenia Market, by Country ($Million), 2023-2035
      • 5.1.3.1 U.S.
      • 5.1.3.2 Canada
  • 5.2 Europe
    • 5.2.1 Market Dynamics
    • 5.2.2 Market Sizing and Forecast
    • 5.2.3 Europe Sarcopenia Market, by Country ($Million), 2023-2035
      • 5.2.3.1 U.K.
      • 5.2.3.2 France
      • 5.2.3.3 Germany
      • 5.2.3.4 Rest-of-Europe
  • 5.3 Asia-Pacific
    • 5.3.1 Market Dynamics
    • 5.3.2 Market Sizing and Forecast
    • 5.3.3 Asia-Pacific Sarcopenia Market, by Country ($Million), 2023-2035
      • 5.3.3.1 Japan
      • 5.3.3.2 China
      • 5.3.3.3 India
      • 5.3.3.4 Rest-of-Asia-Pacific
  • 5.4 Rest-of-the-World
    • 5.4.1 Market Dynamics
    • 5.4.2 Market Sizing and Forecast
    • 5.4.3 Rest-of-the-World Sarcopenia Market, by Country ($Million), 2023-2035
      • 5.4.3.1 Latin America
      • 5.4.3.2 Middle East and Africa

6. Global Sarcopenia Market Competitive Landscape and Company Profiles

  • 6.1 Competitive Landscape
    • 6.1.1 Mergers and Acquisitions
    • 6.1.2 Partnership, Alliances and Business Expansion
    • 6.1.3 New Offerings
    • 6.1.4 Regulatory Activities
    • 6.1.5 Funding Activities
  • 6.2 Company Profiles
    • 6.2.1 Nestle Health Science
      • 6.2.1.1 Overview
      • 6.2.1.2 Top Products / Product Portfolio
      • 6.2.1.3 Top Competitors
      • 6.2.1.4 Target Customers/End-Users
      • 6.2.1.5 Key Personnel
      • 6.2.1.6 Analyst View
    • 6.2.2 Abbott Laboratories
      • 6.2.2.1 Overview
      • 6.2.2.2 Top Products / Product Portfolio
      • 6.2.2.3 Top Competitors
      • 6.2.2.4 Target Customers/End-Users
      • 6.2.2.5 Key Personnel
      • 6.2.2.6 Analyst View
    • 6.2.3 Bayer AG
      • 6.2.3.1 Overview
      • 6.2.3.2 Top Products / Product Portfolio
      • 6.2.3.3 Top Competitors
      • 6.2.3.4 Target Customers/End-Users
      • 6.2.3.5 Key Personnel
      • 6.2.3.6 Analyst View
    • 6.2.4 Sanofi S.A.
      • 6.2.4.1 Overview
      • 6.2.4.2 Top Products / Product Portfolio
      • 6.2.4.3 Top Competitors
      • 6.2.4.4 Target Customers/End-Users
      • 6.2.4.5 Key Personnel
      • 6.2.4.6 Analyst View
    • 6.2.5 Novartis AG
      • 6.2.5.1 Overview
      • 6.2.5.2 Top Products / Product Portfolio
      • 6.2.5.3 Top Competitors
      • 6.2.5.4 Target Customers/End-Users
      • 6.2.5.5 Key Personnel
      • 6.2.5.6 Analyst View
    • 6.2.6 Eli Lilly and Company
      • 6.2.6.1 Overview
      • 6.2.6.2 Top Products / Product Portfolio
      • 6.2.6.3 Top Competitors
      • 6.2.6.4 Target Customers/End-Users
      • 6.2.6.5 Key Personnel
      • 6.2.6.6 Analyst View
    • 6.2.7 MyoPax GmbH
      • 6.2.7.1 Overview
      • 6.2.7.2 Top Products / Product Portfolio
      • 6.2.7.3 Top Competitors
      • 6.2.7.4 Target Customers/End-Users
      • 6.2.7.5 Key Personnel
      • 6.2.7.6 Analyst View
    • 6.2.8 Amgen Inc.
      • 6.2.8.1 Overview
      • 6.2.8.2 Top Products / Product Portfolio
      • 6.2.8.3 Top Competitors
      • 6.2.8.4 Target Customers/End-Users
      • 6.2.8.5 Key Personnel
      • 6.2.8.6 Analyst View
    • 6.2.9 Pfizer Inc
      • 6.2.9.1 Overview
      • 6.2.9.2 Top Products / Product Portfolio
      • 6.2.9.3 Top Competitors
      • 6.2.9.4 Target Customers/End-Users
      • 6.2.9.5 Key Personnel
      • 6.2.9.6 Analyst View
    • 6.2.10 GlaxoSmithKline plc
      • 6.2.10.1 Overview
      • 6.2.10.2 Top Products / Product Portfolio
      • 6.2.10.3 Top Competitors
      • 6.2.10.4 Target Customers/End-Users
      • 6.2.10.5 Key Personnel
      • 6.2.10.6 Analyst View
    • 6.2.11 Others

7. Research Methodology

List of Figures

  • Figure: Sarcopenia Market (by Scenario), $Million, 2024, 2028, and 2035
  • Figure: Global Sarcopenia Market, 2024 and 2035
  • Figure: Global Sarcopenia Market Key Trends, Impact Analysis, 2023-2035
  • Figure: North America Sarcopenia Market, $Million, 2023-2035
  • Figure: Europe Sarcopenia Market, $Million, 2023-2035
  • Figure: Asia-Pacific Sarcopenia Market, $Million, 2023-2035
  • Figure: Rest of the World Sarcopenia Market, $Million, 2023-2035

List of Tables

  • Table: Market Snapshot
  • Table: Global Sarcopenia Market (by Treatment Class), $Million, 2023-2035
  • Table: Global Sarcopenia Market (by Route of Administration), $Million, 2023-2035
  • Table: Global Sarcopenia Market (by Distribution Channel), $Million, 2023-2035
  • Table: Global Sarcopenia Market (by Region), $Million, 2023-2035